Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Bibliographic Details
Main Authors: Zarir F. Udwadia, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Wen Wu, Cynthia F. Caracta, Monika Tandon
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221001144

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221001144

Similar Items